SCHEMBL4080143

SCHEMBL4080143

CCOC(=O)c1ccc2cc(-c3n[nH]c4ccc(-c5nc(CN6CCCC6)n[nH]5)cc34)ccc2c1C(N)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 6/20 0.39
WNT1 P04628 6/20 0.39
CLK2 P49760 3/20 0.39
CLK3 P49761 1/20 0.39
CSNK1D P48730 2/20 0.37
MAPK8 P45983 2/20 0.36
TTK P33981 1/20 0.36
JAK2 O60674 3/20 0.35
JAK3 P52333 3/20 0.35
GAK O14976 1/20 0.35
DYRK3 O43781 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
NQO2 P16083 1/20 0.35
CSNK2A2 P19784 1/20 0.35
FECH P22830 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
MAPK9 P45984 1/20 0.35
CSNK1A1 P48729 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4085589 0.85 CSNK1D (0.42) DYRK1AWNT1CLK2CSNK1DMAPK8
SCHEMBL4179665 0.80 CSNK1D (0.46) DYRK1AWNT1CLK2CLK3CSNK1D
SCHEMBL4084647 0.77 CLK2 (0.46) DYRK1AWNT1CLK2CLK3CSNK1D
SCHEMBL5817740 0.76 CSNK1D (0.46) DYRK1AWNT1CLK2CLK3CSNK1D
SCHEMBL13876985 0.76 CSNK1D (0.47) DYRK1AWNT1CLK2CLK3CSNK1D
SCHEMBL4080138 0.75 CSNK1D (0.42) DYRK1AWNT1CSNK1D
SCHEMBL4083131 0.75 CSNK1D (0.45) DYRK1AWNT1CLK2CLK3CSNK1D
SCHEMBL4084821 0.74 CSNK1D (0.57) DYRK1AWNT1CLK2CLK3CSNK1D
SCHEMBL4169696 0.74 CSNK1D (0.47) DYRK1AWNT1CLK2CLK3CSNK1D
SCHEMBL13811892 0.73 LRRK2 (0.50) CLK2TTKGSK3BCHEK1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 DYRK1A 461/4885WNT1 4/4885CLK2 654/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 DYRK1A 354/4885WNT1 4/4885CLK2 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.